KuDOS Pharma Ltd v. Natco Pharma Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: KuDOS Pharmaceuticals Limited (England and Wales); The University of Sheffield (England and Wales)
  • Defendant: Natco Pharma Limited (Republic of India); Natco Pharma Inc. (Delaware); NATCO Pharma USA LLC (Delaware)
  • Plaintiff's Counsel: FBT Gibbons LLP
• Case Identification: 3:26-cv-01711, D.N.J., 02/20/2026
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendants Natco Pharma Inc. and NATCO Pharma USA LLC have regular and established places of business in the district and have allegedly committed, or will commit, acts of infringement there. Venue is asserted over Natco Pharma Limited as a foreign corporation subject to personal jurisdiction in the district.
• Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the cancer drug ZEJULA (niraparib) constitutes an act of infringement of a patent covering a method for treating specific types of cancer.
• Technical Context: The technology relates to targeted cancer therapy using Poly (ADP-ribose) Polymerase (PARP) inhibitors, which are designed to be selectively lethal to cancer cells that have defects in a DNA repair pathway known as homologous recombination.
• Key Procedural History: The litigation was initiated under the Hatch-Waxman Act following a Notice Letter from Natco to Plaintiff The University of Sheffield. In that letter, Natco stated it had filed an ANDA with a Paragraph IV Certification, asserting that the patent-in-suit is invalid, unenforceable, and/or not infringed by its proposed generic product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,859,562 - "Use of RNAi Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer"

• Patent Identification: U.S. Patent No. 8,859,562, "Use of RNAi Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer," issued October 14, 2014 ('562 Patent).

The Invention Explained

• Problem Addressed: The patent describes a need for cancer treatments that are both effective and selective in killing cancer cells, without the associated damage to healthy, non-cancerous cells that is a common side effect of conventional radio- and chemotherapy treatments '562 Patent, col. 2:1-8
• The Patented Solution: The invention is based on the discovery that cancer cells deficient in the homologous recombination (HR) DNA repair pathway are hypersensitive to agents that inhibit a different DNA repair enzyme, Poly(ADP-ribose) Polymerase (PARP) '562 Patent, col. 2:9-14 This creates a "synthetic lethality," where inhibiting PARP is toxic to HR-deficient cancer cells (such as those with BRCA1 or BRCA2 gene mutations) but is not harmful to normal cells with functional HR pathways '562 Patent, abstract '562 Patent, col. 2:37-48 The treatment selectively targets a vulnerability unique to these cancer cells.
• Technical Importance: This synthetic lethality approach represented a significant development in personalized medicine, providing a targeted therapy for patients with cancers caused by specific genetic defects in DNA repair pathways '562 Patent, col. 2:44-48

Key Claims at a Glance

• The complaint asserts independent claim 1 '562 Patent, claim 1 Compl. ¶31
• The essential elements of claim 1 are:
  • A method of treatment of cancer cells defective in homologous recombination (HR).
  • Identifying a human patient with a familial predisposition to gene-linked hereditary cancer, wherein said cancer comprises cancer cells defective in HR.
  • Identifying a compound which inhibits PARP-1.
  • Administering to said human patient a therapeutically effective amount of said compound.
• The complaint does not explicitly reserve the right to assert other claims.

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is Natco's proposed generic version of ZEJULA (niraparib) tablets, in 100 mg, 200 mg, and 300 mg dosages, as described in Natco's ANDA No. 221116 ("Natco's ANDA Product") Compl. ¶1

Functionality and Market Context

• The complaint identifies niraparib, the active pharmaceutical ingredient in ZEJULA and Natco's ANDA Product, as a PARP inhibitor Compl. ¶21 The infringement alleged is not the product itself, but the use of the product for treating cancer as will be directed by Natco's proposed prescribing information and labeling Compl. ¶31
• The action arises from the statutory act of infringement created by the submission of an ANDA seeking FDA approval to market a generic drug prior to the expiration of patents listed in the FDA's Orange Book Compl. ¶1 Compl. ¶30 The complaint alleges that methods of using ZEJULA are covered by claim 1 of the '562 patent Compl. ¶29

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'562 Patent Infringement Allegations

• Identified Points of Contention:
  • Scope Questions: A central dispute may concern the "identifying a human patient" step. The analysis will question whether Natco's proposed label will require physicians to perform a specific diagnostic or familial history evaluation that meets this limitation, or if the prescribed indications for use are broader.
  • Technical Questions: A key question is whether the scientific evidence supports that all cancers for which Natco's product will be indicated are "defective in homologous recombination" as the term is used in the patent. The breadth of the approved uses on the proposed label will be compared against the scope of this claim term.

V. Key Claim Terms for Construction

• The Term: "defective in homologous recombination (HR)"

• Context and Importance: This term defines the specific patient population for the claimed method. Its construction will determine which cancer types and genetic profiles fall within the patent's scope. A narrow construction could limit the claim to patients with specific, tested mutations (e.g., in BRCA1/2), while a broader one might encompass cancers where HR deficiency is presumed or associated with the disease type.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification provides a non-exhaustive list of genes with a "suggested function in HR," including BRCA1, BRCA2, RAD51, ATM, and others, implying the term is not limited to just one or two genes '562 Patent, col. 3:7-18
  • Evidence for a Narrower Interpretation: The specification's examples and background focus heavily on BRCA1 and BRCA2 as the primary examples of HR-defective genes, which a defendant may argue cabin the scope of the invention to those specific, well-characterized defects '562 Patent, col. 3:20-40

• The Term: "identifying a human patient with a familial predisposition to gene-linked hereditary cancer"

• Context and Importance: This is an active step in the method claim, and its meaning is critical for determining infringement. Practitioners may focus on this term because infringement of a method claim via a drug label often turns on whether the label directs or requires the performance of each specific step. The dispute will likely be over what actions satisfy "identifying."

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: A party could argue that "identifying" is satisfied when a physician diagnoses a patient with a type of cancer known to have a strong hereditary link (e.g., certain ovarian or breast cancers), without necessarily requiring a specific genetic test or detailed family pedigree.
  • Evidence for a Narrower Interpretation: The language "gene-linked hereditary cancer" could be argued to require more than a general diagnosis, such as confirmation through genetic testing or a formal assessment of family history that points to a specific genetic inheritance pattern.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both active inducement and contributory infringement Compl. ¶35 The basis for inducement is the allegation that Natco's proposed product labeling will instruct physicians and patients to use the generic drug in a manner that directly infringes claim 1 Compl. ¶33 The basis for contributory infringement is the allegation that the product and its labeling are not suitable for substantial non-infringing uses Compl. ¶34
• Willful Infringement: Willfulness is alleged based on Natco's purported knowledge of the '562 Patent, evidenced at least by its submission of a Paragraph IV certification to the FDA, and its subsequent actions "without a reasonable basis for believing" it would not be liable for infringement Compl. ¶32 Compl. ¶36

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of induced infringement: will the final, FDA-approved language on Natco's generic label instruct or encourage physicians to perform every step of the asserted method claim? The outcome may depend on whether the label's indications for use are coextensive with the claim limitations, particularly the step of "identifying a human patient with a familial predisposition."
• The case will also turn on definitional scope: how will the court construe the term "defective in homologous recombination"? Whether this term is limited to specific, confirmed genetic mutations (like BRCA1/2) or extends more broadly to cancer types associated with HR deficiency will be a critical determinant of the patent's reach.